MDGL
Price
$301.00
Change
-$7.79 (-2.52%)
Updated
Apr 24, 10:48 AM (EDT)
Capitalization
6.82B
19 days until earnings call
PTN
Price
$0.20
Change
+$0.01 (+5.26%)
Updated
Apr 24, 10:43 AM (EDT)
Capitalization
5.46M
26 days until earnings call
Ad is loading...

MDGL vs PTN

Header iconMDGL vs PTN Comparison
Open Charts MDGL vs PTNBanner chart's image
Madrigal Pharmaceuticals
Price$301.00
Change-$7.79 (-2.52%)
Volume$150
Capitalization6.82B
Palatin Technologies
Price$0.20
Change+$0.01 (+5.26%)
Volume$1.98K
Capitalization5.46M
MDGL vs PTN Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. PTN commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and PTN is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (MDGL: $308.79 vs. PTN: $0.19)
Brand notoriety: MDGL and PTN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 95% vs. PTN: 112%
Market capitalization -- MDGL: $6.82B vs. PTN: $5.46M
MDGL [@Biotechnology] is valued at $6.82B. PTN’s [@Biotechnology] market capitalization is $5.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whilePTN’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • PTN’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than PTN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 4 TA indicator(s) are bullish while PTN’s TA Score has 4 bullish TA indicator(s).

  • MDGL’s TA Score: 4 bullish, 5 bearish.
  • PTN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PTN is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а +0.33% price change this week, while PTN (@Biotechnology) price change was -20.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.52%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was -12.85%.

Reported Earning Dates

MDGL is expected to report earnings on Aug 06, 2025.

PTN is expected to report earnings on Oct 07, 2025.

Industries' Descriptions

@Biotechnology (+6.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.82B) has a higher market cap than PTN($5.46M). MDGL YTD gains are higher at: 0.071 vs. PTN (-82.432). PTN has higher annual earnings (EBITDA): -26.62M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. PTN (3.42M). PTN has less debt than MDGL: PTN (358K) vs MDGL (120M). MDGL has higher revenues than PTN: MDGL (180M) vs PTN (350K).
MDGLPTNMDGL / PTN
Capitalization6.82B5.46M124,849%
EBITDA-450.12M-26.62M1,691%
Gain YTD0.071-82.432-0%
P/E RatioN/AN/A-
Revenue180M350K51,429%
Total Cash926M3.42M27,100%
Total Debt120M358K33,520%
FUNDAMENTALS RATINGS
MDGL vs PTN: Fundamental Ratings
MDGL
PTN
OUTLOOK RATING
1..100
5720
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
30100
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
4498
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
3150

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (67) in the Pharmaceuticals Other industry is in the same range as PTN (73) in the Biotechnology industry. This means that MDGL’s stock grew similarly to PTN’s over the last 12 months.

MDGL's Profit vs Risk Rating (30) in the Pharmaceuticals Other industry is significantly better than the same rating for PTN (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than PTN’s over the last 12 months.

MDGL's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as PTN (99) in the Biotechnology industry. This means that MDGL’s stock grew similarly to PTN’s over the last 12 months.

MDGL's Price Growth Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for PTN (98) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than PTN’s over the last 12 months.

PTN's P/E Growth Rating (95) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that PTN’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLPTN
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KORU39.521.57
+4.14%
Direxion Daily South Korea Bull 3X ETF
PWZ23.120.11
+0.48%
Invesco California AMT-Free Muni Bd ETF
BBAX49.100.15
+0.31%
JPMorgan BetaBuilders Dev APAC ex-JpnETF
VEMY25.840.02
+0.08%
Virtus Stone Harbor Emr Mkt Hi Yld BdETF
FLTB49.970.03
+0.06%
Fidelity Limited Term Bond ETF